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he Association of Fasting Glucose Levels With
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OBJECTIVES The purpose of this study was to determine if fasting glucose levels are an independent risk
factor for congestive heart failure (CHF) in elderly individuals with diabetes mellitus (DM)
with or without coronary heart disease (CHD).
BACKGROUND Diabetes mellitus and CHF frequently coexist in the elderly. It is not clear whether fasting
glucose levels in the setting of DM are a risk factor for incident CHF in the elderly.
METHODS A cohort of 829 diabetic participants, age 65 years, without prevalent CHF, was followed
for five to eight years. The Cox proportional hazards modeling was used to determine the risk
of CHF by fasting glucose levels. The cohort was categorized by the presence or absence of
prevalent CHD.
RESULTS For a 1 standard deviation (60.6 mg/dl) increase in fasting glucose, the adjusted hazard ratios
for incident CHF among participants without CHD at baseline, with or without an incident
myocardial infarction (MI) or CHD event on follow-up, was 1.41 (95% confidence interval
1.24 to 1.61; p  0.0001). Among those with prevalent CHD at baseline, with or without
another incident MI or CHD event on follow-up, the corresponding adjusted hazard ratio
was 1.27 (95% confidence interval 1.02 to 1.58; p  0.05).
CONCLUSIONS Among older adults with DM, elevated fasting glucose levels are a risk factor for incident
CHF. The relationship of fasting glucose to CHF differs somewhat by the presence or
absence of prevalent CHD. (J Am Coll Cardiol 2004;43:2236–41) © 2004 by the
American College of Cardiology Foundationt
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pongestive heart failure (CHF) and diabetes mellitus (DM)
re age-related disorders that frequently coexist (1,2). De-
pite their close association, there is uncertainty whether
levated glucose levels are a risk factor for CHF. Cohort
3–7) and clinic (8–11) studies of people with DM have
eached conflicting results. In a recent analysis of the
iabetic and nondiabetic cohorts of the Cardiovascular
ealth Study (CHS)—a longitudinal study of elderly adults
hose purpose is to identify factors related to the onset and
ourse of cardiovascular disease and stroke—we found that
history of DM predicted CHF, but not a glucose level
125 mg/dl (12). The uncertainty regarding the association
f elevated glucose levels and incident CHF may stem from
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Department of Public Health Sciences, Wake Forest University School of Medicine,
inston-Salem, North Carolina; ¶Department of Pathology, University of Vermont
ollege of Medicine, Colchester, Vermont; #Division of Epidemiology and Clinical
pplications, National Heart, Lung, Blood Institute, National Institutes of Health,
ethesda, Maryland; and the **Center on Aging and Health, Johns Hopkins School
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hrough NO1-HC-85086, NO1-HC-35129, and NO1-HC-15103 from the Na-
ional Heart, Lung, and Blood Institute.
Manuscript received July 29, 2003; revised manuscript received October 15, 2003,
(ccepted October 20, 2003.he fact that CHF is a heterogeneous disorder. It may occur
s a result of myocardial damage secondary to coronary heart
isease (CHD), but may also occur in the absence of CHD
ue to myocardial dysfunction. If elevated glucose levels
ave a differing degree of association with these conditions,
hen the relationship of elevated glucose levels to CHF risk
ould vary as well.
In the present study, we examine the diabetic cohort of
HS to determine the role of fasting glucose levels for
ncident CHF in those with and without CHD at baseline
r on follow-up.
ETHODS
ecruitment methods for CHS have been published (13). In
rief, a random sample of individuals, 65 years of age,
erived from Medicare eligibility lists, and other household
embers65 years, were invited to participate in the study.
otential participants were excluded if they had illnesses
hat were expected to lead to early death. A total of 5,201
articipants were recruited in 1989 to 1990 (called the
riginal cohort), and 687 were recruited in 1992 to 1993 to
rovide additional representation of African Americans
called the new cohort). For these analyses, only participants
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June 16, 2004:2236–41 Fasting Glucose and CHF in Elderly Patients With DMith DM at entry were studied (n  910). All participants
igned informed consent.
Upon entry into the study, participants were invited for a
aseline interview. Information on prescription medications
sed in the preceding two weeks (including insulin and oral
ypoglycemic agents) was collected (14). During a subse-
uent clinic visit, venipuncture was done after an overnight
ast. Plasma and serum were frozen at 70°C, and shipped
o the CHS Central Laboratory (University of Vermont,
urlington, Vermont). Fasting serum chemistry analyses
ere performed (15). Glucose levels were measured on a
odak Ektachem 700 Analyzer (Ektachem Test Method-
logies, Eastman Kodak, Rochester, New York, March
985) and assayed within 30 days. Average monthly coef-
cient of variation was 0.93%. One year after the baseline
xamination, a subset of CHS participants had a hemoglo-
in A1c test performed as part of a substudy.
Echocardiograms were obtained during the baseline ex-
mination for 99.1% of the original cohort in 1989 to 1990.
chocardiograms for the African-American participants
ere obtained in 1994 to 1995, one year after enrollment in
he study. Therefore, these latter echocardiograms are not
sed in this analysis because some incident events may have
ccurred before performing the echocardiogram. Moreover,
aboratory values, medication use, and anthropometric mea-
urements would have differed from the baseline examina-
ion to the time that the echocardiogram was performed.
or those with incident CHF, left ventricular (LV) systolic
unction data was obtained in many (but not all) cases from
chocardiographic reports at the point of care during index
ospitalization or office visit at which the clinical diagnosis
f CHF was made. The reports were reviewed by CHS
nvestigators.
efinitions. Diabetes mellitus was defined by a fasting
lucose 126 mg/dl or the use of antidiabetic agents.
elf-report of DM was not a defining criterion. Subjects
ho were not fasting at blood draw or whose diabetic status
ould not be determined from medication lists were ex-
luded (n  64).
Baseline and incident CHD was defined as a history of
yocardial infarction (MI) or a non-MI event, such as
ngina pectoris, or a revascularization procedure (coronary
rtery bypass grafting or percutaneous transluminal coronary
ngioplasty).
Global LV function was qualitatively assessed from the
aseline two-dimensional echocardiogram as normal, bor-
Abbreviations and Acronyms
CHD coronary heart disease
CHF  congestive heart failure
CHS  Cardiovascular Health Study
DM  diabetes mellitus
LV  left ventricle/ventricular
MI  myocardial infarctionerline, or abnormal ejection fraction. Inter-reader agree- Tent was 94%, and intra-reader agreement was 98% of
aired studies (16). Qualitatively assessed normal LV func-
ion on the echocardiogram corresponded to an ejection
raction 55%, borderline was 45% to 54%, abnormal was
45%.
The diagnosis of incident CHF was based on data from
n index hospitalization, outpatient visits for CHF, or
elf-report of a physician diagnosis of CHF (17). These
eports were confirmed by documentation in the partici-
ant’s medical records of a constellation of symptoms
dyspnea, fatigue, orthopnea, paroxysmal nocturnal dys-
nea) and physical signs (edema, pulmonary rales, gallop
hythm, displaced LV apical impulse), and by supporting
linical findings such as chest X-ray and medications
digoxin, hydralazine, or loop diuretics). Supporting clinical
ndings were adjudicated by the CHS events committee,
hich classified all cardiovascular events (17).
Analyses for this study are based on events through June
998. Follow-up was 95% complete for the original and
he African-American cohorts based on telephone contact
nd review of Medicare data tapes.
tatistical methods. Baseline characteristics of the cohort,
ategorized by development of CHF, were compared using
he chi-square test for discrete values and the t test for
ontinuous data. The Cox proportional hazards models
ere used to examine the effect of fasting glucose levels on
ncident CHF. A fasting glucose of 200 mg/dl was approx-
mately the 80th percentile of this cohort. Models were
enerated in stages. Demographic, laboratory, and clinical
easures were taken first. Once significant predictors were
dentified, time-dependent variables (new MI or non-MI
HD event) were added to each model to evaluate the risk
f these events on CHF. To determine the risk associated
ith fasting glucose in those without baseline CHD or an
ncident MI/other CHD event before the occurrence of
ncident CHF, significant interactions of risk factors and
ime-dependent variables were included in the model. At
ach stage, stepwise selection was used with a value of p 
.05. All analyses were done using SPSS Version 11.0
SPSS Inc., Chicago, Illinois).
ESULTS
here were 910 participants in CHS with DM at baseline
15.5% of the two cohorts combined). Of these, 81 (8.9%)
ad prevalent CHF and were not considered in this analysis.
f the remaining 829 participants, there were 626 without
linical CHD and 203 with clinical CHD at baseline
Fig. 1).
ncident CHF in those without baseline CHD. There
ere 123 incident CHF events among the 626 individuals
ithout CHD at baseline—55 after an incident CHD/MI
vent, and 68 without an incident CHD/MI event. Baseline
haracteristics of these 626 participants, categorized by
evelopment or absence of incident CHF, are shown in
able 1. Those who developed CHF were older, more
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Fasting Glucose and CHF in Elderly Patients With DM June 16, 2004:2236–41entrally obese, and had higher systolic blood pressure,
asting glucose, uric acid, and C-reactive protein levels than
hose who did not develop CHF. They did not differ
ignificantly with respect to LV function at baseline or
ypoglycemic medication use. Systolic LV function at
aseline was usually normal. At the time of hospitalization
or the incident CHF, LV function was preserved in more
han one-half of cases (among those with no MI or CHD
vent before CHF, 14 of 32 [43.8%] had abnormal ejection
igure 1. Incident congestive heart failure (CHF) in the diabetic cohort of
he Cardiovascular Health Study (CHS) categorized by the absence or
resence of coronary heart disease (CHD). MI  myocardial infarction.
Table 1. Baseline Characteristics of the CHS D
Baseline Categorized by Incidence of CHF
Baseline Characteristic
N
n
Gender (% male)
Age (yrs) 72
Systolic blood pressure (mm Hg) 140
Diastolic blood pressure (mm Hg) 71
BMI (kg/m2) 28
Hip circumference (cm) 104
Waist circumference (cm) 100
Smoking (%)
Never
Former
Current
Diabetic medications (%)
None
OHGA
Insulin  OHGA
LV function at baseline (%)*
Normal (n  477)
Borderline (n  33)
Abnormal (n  13)
LV function at hospitalization (%)†
Normal (n  27)
Borderline (n  9)
Abnormal (n  26)
Fasting glucose (mg/dl) 166
Fasting insulin (uIU/ml) 30
Uric acid (mg/dl) 5
Creatinine (mg/dl) 1
C reactive protein (mg/l) 4
Albumin (mg/dl) 4
*In those without an incident CHF event in the original coh
data available. Values are means and SD. Only statistically s
BMI  body mass index; CHF  congestive heart fail
OHGA  oral hypoglycemic agents.raction; among those with MI or CHD event before CHF,
2 of 30 [40.0%] had abnormal ejection fraction).
The incident rate of CHF in the cohort was 31.1 cases
er 1,000 person-years. The rate in nondiabetic CHS
articipants without baseline CHD was 12.7 cases per 1,000
erson-years. The incidence rates of CHF events per 1,000
atient-years of follow-up by fasting glucose quartiles are
hown in Table 2. There was a near doubling of rate in the
nd and 3rd quartiles as compared with the 1st quartile
31.8 and 28.8 cases per 1,000 patient-years, respectively, vs.
7.7). There was a near tripling in rate in the 4th quartile
tic Cohort Without Clinical CHD at
F
3
CHF
n  123 p Value
48.0
.4) 73.7 (5.5) 0.03
1.6) 148.5 (20.1)  0.001
1.4) 73.0 (14.2)
.8) 29.2 (4.9)
0.0) 107.8 (10.7) 0.003
2.2) 103.2 (13.8) 0.01
42.3
44.7
13.0
42.3
36.6
21.1
86.3
10.8
2.9
43.5
14.5
42.0
2.5) 190.0 (83.0)  0.001
9.0) 38.1 (67.8)
.5) 6.0 (1.6) 0.03
.5) 1.1 (0.4)
.0) 6.8 (12.3) 0.03
.3) 4.0 (0.3)
or those with incident CHF in the original cohort, 98 had
ant p values are shown.
HS  Cardiovascular Health Study; LV  left ventricle;
able 2. Incidence Rates of CHF in 1,000 Person-Years for
hose Without Prevalent CHD at Baseline Categorized by
uartiles of Fasting Glucose Levels
Glucose
Quartile* n
Incident
CHF Events
Incidence
Rate
I 158 18 17.7
II 153 32 31.8
III 157 29 28.8
IV 158 44 47.7
Quartiles of fasting glucose (mg/dl): I  61 to 132; II  133 to 152; III  153 to
90; IV  191 to 657.
CHF  congestive heart failure; CHD  coronary heart disease; n  the number
n each quartile.iabe
o CH
 50
45.9
.6 (5
.6 (2
.8 (1
.5 (4
.7 (1
.1 (1
49.3
39.8
10.9
53.7
29.6
16.7
92.4
5.2
2.4
.6 (5
.0 (4
.7 (1
.0 (0
.7 (9
.0 (0
ort; †F
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June 16, 2004:2236–41 Fasting Glucose and CHF in Elderly Patients With DM47.7 cases per 1,000 patient-years) relative to the 1st
uartile.
Results of the Cox proportional hazards models examin-
ng the effect of fasting glucose on incident CHF risk are
hown in Table 3. In unadjusted analysis, a 1 standard
eviation increase in fasting glucose level (60.6 mg/dl) was
ssociated with a 37% increased risk of CHF (model I, p 
.0001). When adjustment was made for other baseline risk
actors, a further increase in association of fasting glucose
ith incident CHF was found (model II, p  0.0001).
ddition of time-dependent variables (incident MI or other
HD event) did not change this association (model III, p
.0001). A test for interaction between fasting glucose levels
nd incident MI before incident CHF was not significant,
uggesting the effect of glucose on CHF did not differ by the
resence or absence of incident MI. Several other significant
nteractions between incident MI and baseline variables had
ittle effect on the risk associated with fasting glucose levels
nd CHF (data not shown). When analysis was repeated
ith fasting glucose levels as quartiles, there was an increase
n risk from the first to the 2nd and 3rd quartiles. There was
further increase in the 4th quartile. With adjustment for
aseline factors (model II) and incident MI and CHD
vents (model III), the association of fasting glucose with
HF increased, especially for those in the 4th quartile.
ncident CHF in those with baseline CHD. There were
03 participants at baseline without CHF who had clinical
HD. Among them, 83 incident CHF events occurred for
rate of 78.3 cases per 1,000 person-years. The rate in
ondiabetic CHS participants with baseline CHD was 30.9
ases per 1,000 person-years. Among those for whom
chocardiographic data was available at the time of the
HF event, 12 of 21 (57.1%) had an abnormal ejection
raction without an additional incident MI or CHD event,
nd 7 of 15 (46.7%) had an abnormal ejection fraction with
n incident MI or CHD event.
In unadjusted analysis, a 1 standard deviation increase in
asting glucose level (60.6 mg/dl) was associated with a 16%
ncreased risk of CHF (model I, p 0.15) (Table 4). When
Table 3. Cox Regression Models of the Associ
Increase of Fasting Glucose (60.6 mg/dl) and a
CHF Among Diabetic Participants in the CH
Model I
Fasting glucose increase
of 60.6 mg/dl
1.37 (1.21, 1.56)
Fasting glucose quartiles
1st 1.00
2nd 1.81 (1.00, 3.28)
3rd 1.67 (0.92, 3.04)
4th 2.91 (1.66, 5.09)
Continuous fasting glucose hazard ratios are in SD units of 6
 133 to 152; III  153 to 190; IV  191 to 657. *Adjusted
level, smoking status (never, former, present), body mass ind
use (as compared with no treatment for diabetes mellitus i.e.
predictors of congestive heart failure (CHF), except insulin
infarction and coronary heart disease (CHD) event before C
CHS  Cardiovascular Health Study.djustment was made for other baseline risk factors, an increase in association was found (model II, p  0.05).
ddition of time-dependent variables (incident MI or other
HD event) did not significantly change this association
model III, p  0.05). When the analysis was repeated with
asting glucose levels as quartiles, there was an increase in
isk for CHF in the 4th quartile relative to the other
uartiles, especially in models II and III.
orrelation coefficient. Of the 829 individuals in this
tudy, 136 had a hemoglobin A1c test done one year after
he baseline examination. The correlation coefficient be-
ween the baseline fasting glucose levels and percent hemo-
lobin A1c was 0.59 (p  0.000001).
ISCUSSION
his study shows that fasting glucose levels are related to
HF risk in older adults with DM. Among those without
revalent CHD, our models show an40% increase in risk.
mong those with prevalent CHD, the risk of CHF
ssociated with elevated fasting glucose level is also present
ut not as strong. The relationship, however, is not well
stimated because of the small number of participants in the
roup.
Raised glucose levels may lead to CHF in the absence of
HD by several mechanisms. Raised levels may reflect
oorer compliance with medications or poorer medical care.
n this study, however, the use of hypoglycemic agents was
he same in those who did or did not develop CHF. Second,
yperglycemia impairs endothelial function and vasodila-
ion, impeding the ability of coronary arteries to increase
yocardial blood flow (18). Finally, elevated glucose levels
ay have a deleterious effect on the myocardium leading to
brosis and stiffness (19–23) with diminished diastolic
lling. Diastolic dysfunction has been described as a cause of
HF in adults with DM (24). In CHS, most participants
ith CHF had normal, or borderline, impairment of systolic
unction, presumably reflecting isolated diastolic heart fail-
re (25,26).
We have previously shown that incident CHD among
of Fasting Blood Glucose Level per 1 SD
artiles of Fasting Glucose Levels on Incident
ithout Baseline CHD
Model II* Model III†
1.41 (1.24, 1.62) 1.41 (1.24, 1.61)
1.00 1.00
1.51 (0.83, 2.75) 1.73 (0.94, 3.20)
1.80 (0.99, 3.30) 1.88 (1.02, 3.46)
3.45 (1.94, 6.15) 3.64 (2.04, 6.49)
g/dl. Quartiles of fasting glucose (mg/dl): I  61 to 132; II
ge, systolic blood pressure, C reactive protein level, uric acid
ist circumference, and oral hypoglycemic agents, and insulin
diagnosed diabetes mellitus). All are statistically significant
Adjusted for factors in model II plus incident myocardial
ll are significant predictors of CHF other than insulin use.ation
s Qu
S W
0.6 m
for a
ex, wa
, newly
use. †
HF. Andividuals with glucose disorders is related to elevated
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Fasting Glucose and CHF in Elderly Patients With DM June 16, 2004:2236–41asting glucose levels (27). In that analysis, 20 mg/dl
ncrements of fasting glucose levels increased CHD risk by
% (95% confidence interval 1.00 to 1.12). Thus, it is not
urprising that in those in whom CHF occurred in associ-
tion with prevalent CHD that the risk of CHF was
ssociated with the fasting glucose level.
Several other points regarding our results should be
oted. First, of the total CHF events in this diabetic cohort,
nly 33% (68 of 206) occurred in the absence of clinical
HD. This value is lower than that found in the Framing-
am Heart study (28). This difference, in all likelihood,
eflects the higher rate of CHD in people with DM.
econd, among those in whom echocardiographic reports
ere available at the time of CHF diagnosis, 45% to 60%
ad normal or borderline systolic ventricular function (de-
ending on prevalent or incident MI or CHD events). This
s in keeping with recent population-based data (29). Third,
pproximately one-half of the cohort had untreated DM.
ost were newly diagnosed diabetic individuals. This is
imilar to prior studies of DM in which one-half of
ndividuals with DM are unaware of having it (30).
The strength of this study is its methodology. It allowed
or the evaluation of baseline risk factors as well as incident
vents. It was population-based and included women and
inorities. Disadvantages of this study should also be noted.
irst, institutionalized individuals and those with short life
xpectancy were excluded. Thus, the sample is primarily of
he relatively healthy elderly, and results cannot be extrap-
lated to those who were very ill. On the other hand, the
elatively long follow-up of CHS should diminish this
ffect. Second, a fasting glucose level was used and not a
easure of overall glucose control, such as glycosylated
emoglobin. Many epidemiological studies rely on fasting
lucose levels. There was, however, a strong correlation
etween the baseline fasting glucose level and the hemoglo-
in A1c level in a subset of the study cohort done one year
fter baseline testing. This suggests that the fasting glucose
Table 4. Cox Regression Models of the Associ
Increase of Fasting Glucose (60.6 mg/dl) and a
CHF Among Diabetic Participants in the CH
MI or CHD Event
Model I
Fasting glucose increase
of 60.6 mg/dl
1.16 (0.95, 1.41)
Fasting glucose quartiles
1st 1.00
2nd 0.64 (0.33, 1.25)
3rd 1.03 (0.56, 1.89)
4th 1.39 (0.79, 2.44)
Continuous fasting glucose hazard ratios are in SD units of 6
 133 to 152; III  153 to 190; IV  191 to 657. *Adjusted
level, smoking status (never, former, present), body mass ind
use (as compared with no treatment for diabetes mellitus, i.e.
predictors of congestive heart failure (CHF), except insulin
infarction (MI) and coronary heart disease (CHD) event bef
use.
CHS  Cardiovascular Health Study.evel was related to overall glucose control. It also suggestshat elevated glucose levels tracked over time and reflected
ontinued elevated levels. Third, angiographic data are not
vailable in CHS. The degree of underlying CHD in those
ithout clinical CHD, therefore, cannot be assessed.
In conclusion, elevated fasting glucose levels in older
dults with DM are associated with the risk of CHF in both
hose with and without MI/CHD. Ongoing prospective
iabetes studies, such as the Action to Control Cardiovas-
ular Risk in Diabetes (ACCORD) trial, will be able to
etermine if better glucose control results in a reduction of
HF risk.
eprint requests and correspondence: Dr. Joshua I. Barzilay,
aiser Permanente of Georgia, 200 Crescent Center Parkway,
ucker, Georgia 30084. E-mail: joshua.barzilay@kp.org.
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